GPCR allosteric agonist - Iambic Therapeutics
Latest Information Update: 03 Dec 2024
Price :
$50 *
At a glance
- Originator Iambic Therapeutics
- Class
- Mechanism of Action G protein-coupled receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase Unknown Unspecified
Most Recent Events
- 15 Oct 2024 Investigation in Unspecified in USA (unspecified route), prior to October 2024 (Iambic Therapeutics pipeline, October 2024)